Debiopharm, a Swiss-based global biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells
Antibody Degraducer Conjugates | 17/06/2021 | By Darshana | 331
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy